Literature DB >> 35018643

Clinical effects of low-dose esketamine for anaesthesia induction in the elderly: A randomized controlled trial.

Juan Li1, Zhongyu Wang1, Anqi Wang1, Zhaoyang Wang1.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Esketamine is an N-methyl-D-aspartic acid (NMDA) receptor antagonist, which has stronger sedative and analgesic effects and fewer adverse events than ketamine. The effects of low-dose esketamine on haemodynamics and postoperative quality of recovery in elderly patients have not been evaluated. To evaluate whether low-dose esketamine can be safely used for anaesthesia induction in the elderly.
METHODS: Eighty elderly patients were selected for unilateral total knee replacement under general anaesthesia from February 2021 to August 2021. Patients were randomly divided into two groups (n = 40): control group (C group) and esketamine group (K group). During induction of anaesthesia, the control group was intravenously injected with normal saline of equal volume, and the esketamine group was intravenously injected with 0.2-mg/kg esketamine. Both groups were induced by etomidate, sufentanil and rocuronium and maintained by combined intravenous and inhaled anaesthesia during operation. MAIN OUTCOME MEASURES: HR, SBP, DBP, MAP and BIS values were recorded before induction of anaesthesia (T0 ), immediately before endotracheal intubation (T1 ), 1min(T2 ) and 5min(T3 ) after endotracheal intubation, surgical skin incision (T4 ), 1min(T5 ) and 5min(T6 ) after surgical skin incision.
RESULTS: Compared with the C group, SBP, DBP, MAP, HR and BIS of the K group were significantly higher at T1 -T3 (p < 0.05). There were no significant differences in SBP, DBP, MAP, HR and BIS between the two groups at T4 -T6 (p > 0.05). Compared with T0 , SBP, MAP and BIS values of the two groups at T1 -T6 were decreased (p < 0.05). DBP of the K group at T2 was not significantly different from DBP at T0 (p < 0.05), but DBP of the C group decreased from T1 to T6 (p < 0.05). Compared with T0 , HR in both groups decreased at T1 , T3 , T4 , T5 and T6 (p < 0.05). Compared with the C group, the incidence of cough in the K group was significantly lower (p < 0.05); There was no significant difference in the number of myoclonus during induction between the two groups (p > 0.05). Compared with the C group, the number of hypotension episodes in the K group during induction was much smaller (p < 0.05). There were no significant differences in the incidence of hypertension, bradycardia and tachycardia (p > 0.05). There were no significant differences in postoperative recovery quality and incidence of adverse events between the two groups (p > 0.05). WHAT IS NEW AND
CONCLUSION: Low-dose esketamine for anaesthesia induction in the elderly undergoing knee arthroplasty may better maintain the stability of haemodynamics and has no adverse effect on the quality of early recovery after operation.
© 2022 John Wiley & Sons Ltd.

Entities:  

Keywords:  delirium; esketamine; hypotension; postoperative recovery; the elderly

Mesh:

Substances:

Year:  2022        PMID: 35018643     DOI: 10.1111/jcpt.13604

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  3 in total

1.  Subanaesthetic dose of esketamine during induction delays anaesthesia recovery a randomized, double-blind clinical trial.

Authors:  Cao Zhang; Jiangqin He; Qinye Shi; Fangping Bao; Jianhong Xu
Journal:  BMC Anesthesiol       Date:  2022-05-09       Impact factor: 2.376

2.  Esketamine prevents propofol-induced injection pain: Randomized controlled trial.

Authors:  Chaozhi Xu; Xiaotang Wei; Cuiwen Zhang; Xiaofang Huang; Hongmeng Lan; Yanping Xu; Xiaoyan Wu; Fuping Li; Xuehai Guan
Journal:  Front Pharmacol       Date:  2022-09-20       Impact factor: 5.988

3.  Effective dose of propofol combined with a low-dose esketamine for gastroscopy in elderly patients: A dose finding study using dixon's up-and-down method.

Authors:  Yuling Zheng; Yafei Xu; Bixin Huang; Ying Mai; Yiwen Zhang; Zhongqi Zhang
Journal:  Front Pharmacol       Date:  2022-09-20       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.